Skip to content
The African Exponent DATA
Resources

Review pending. Every figure has been checked against its cited source page in an AI-assisted source verification (7 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review

Kakuzi

KUKZ · Nairobi Securities Exchange · Incorporated in Kenya · Consolidated statements

On this page
Company details
Legal name
Kakuzi Plc
Incorporated in
Kenya
Listing
KUKZ on the Nairobi Securities Exchange, active · ISIN KE0000000281 (observed 2026-10-07)
Sector
Agriculture (our classification from the stated principal activity)
Activity
Avocados, macadamia nuts, tea green leaf, forestry and livestock in Kenya.
Financial year ends
31 December

Overview

Year ended 31 December 2025 · annual report, signed / final · source

  • Revenue

    KES 5.37 billion

    5,368,622 KES thousands · p52

    +12.0% vs 2024

  • Operating profit / (loss)

    KES 499 million

    498,772 KES thousands · p52

    Moved from loss to profit (FY2024: (238,913) KES thousands)

  • Profit / (loss) for the year

    KES 388 million

    387,573 KES thousands · p52

    Moved from loss to profit (FY2024: (131,694) KES thousands)

  • Total assets

    Not reported in this filing

  • Total equity

    KES 5.57 billion

    5,568,038 KES thousands · p53

    +4.4% vs 2024

  • Cash from operations

    KES 853 million

    853,151 KES thousands · p57

    +79.7% vs 2024

Large amounts are rounded for reading (KES million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.

Financial statements

Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in KES thousands unless the row says otherwise; brackets are negative.

† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table

Column sources

  • FY2025 — annual report, signed / final; reported for the year · source
  • FY2024 — annual report, signed / final; comparative in the FY2025 filing · source
  • FY2023 — annual report, signed / final; comparative in the FY2024 filing · source

Income statement

Income statement, KES thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), comparative reported in the annual report for 2024.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportcomparative in FY2024 filing
Sales 5,368,622 4,791,692 5,401,468
Gains arising from changes in fair value less costs to sell of non-current biological assets12 98,230 237,956 126,808
Sales plus fair-value gains (unlabelled subtotal)3 5,466,852 5,029,648 5,528,276
Cost of sales (3,573,764) (4,137,314) (3,555,368)
Gross profit 1,893,088 892,334 1,972,908
Other income/(loss)4 16,114 (173,369) 134,310
Selling and distribution costs (1,410,430) (957,878) (1,497,963)
Operating profit/(loss)5 498,772 (238,913) 609,255
Interest income 69,705 72,444 54,760
Finance costs (60) (279) (33)
Profit/(loss) before income tax6 568,417 (166,748) 663,982
Income tax (charge)/credit7 (180,844) 35,054 (210,465)
Profit/(loss) for the year8 387,573 (131,694) 453,517
Other comprehensive income (unlabelled subtotal) 3,955 1,322 2,114
Total comprehensive income/(loss) for the year9 391,528 (130,372) 455,631
Notes and alternative reported figures (9)
  1. “Gains arising from changes in fair value less costs to sell of non-current biological assets” is an issuer-specific line, not mapped to a shared definition: Note 6(i): fair-value gains on non-current biological assets (orchards, plantations), presented with sales.
  2. Printed under different labels across filings: “Gains arising from changes in fair value less costs to sell of”; “Gains arising from changes in fair value less costs to sell of non-current biological assets”.
  3. “Sales plus fair-value gains (unlabelled subtotal)” is an issuer-specific line, not mapped to a shared definition: Unlabelled subtotal printed above cost of sales: sales plus the fair-value gains on biological assets.
  4. Printed under different labels across filings: “Other (loss)/ income”; “Other income/(loss)”.
  5. Printed under different labels across filings: “Operating (loss)/ profit”; “Operating profit/(loss)”.
  6. Printed under different labels across filings: “(Loss)/profit before income tax”; “Profit/(loss) before income tax”.
  7. Printed under different labels across filings: “Income tax (charge)/credit”; “Income tax credit/(charge)”.
  8. Printed under different labels across filings: “(Loss)/profit for the year”; “Profit/(loss) for the year”.
  9. Printed under different labels across filings: “Total comprehensive (loss)/income for the year”; “Total comprehensive income/(loss) for the year”.

Balance sheet

Balance sheet, KES thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), comparative reported in the annual report for 2024.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportcomparative in FY2024 filing
Share capital 98,000 98,000 98,000
Other reserves 40,206 36,251 34,929
Retained earnings 5,116,232 5,042,259 5,330,753
Proposed dividend1 313,600 156,800 470,400
Total equity 5,568,038 5,333,310 5,934,082
Deferred income tax 1,090,524 1,115,532 1,189,385
Post employment benefit obligations 165,515 151,744 109,502
Lease obligations 691 688 326
Non current liabilities (unlabelled subtotal) 1,256,730 1,267,964 1,299,213
Total equity and non current liabilities2 6,824,768 6,601,274 7,233,295
Property, plant and equipment 2,878,343 2,981,247 3,064,961
Biological assets3 1,128,680 1,118,962 935,224
Right of use assets 4,051 4,099 4,187
Non current receivables4 61,817 53,434 50,763
Non current assets (unlabelled subtotal) 4,072,891 4,157,742 4,055,135
Biological assets – growing agricultural produce56 505,002 539,272 800,486
Inventories 465,756 369,464 551,635
Receivables and prepayments 594,723 661,105 628,305
Current tax recoverable –7 81,374 72,420
Cash and cash equivalents 1,593,203 1,106,684 1,408,131
Current assets (unlabelled subtotal) 3,158,684 2,757,899 3,560,977
Payables and accrued expenses 307,131 301,029 329,612
Current tax payable 92,180 –8 Not reported in this filing9
Lease obligations 51 55 201
Post employment benefit obligations10 7,445 13,283 53,004
Current liabilities (unlabelled subtotal) 406,807 314,367 382,817
Net current assets11 2,751,877 2,443,532 3,178,160
Total assets less current liabilities (unlabelled total)12 6,824,768 6,601,274 7,233,295
Less: fixed deposit – maturity over three months13 60,000 –14 Not reported in this filing15
Financial assets held at amortised cost16 Not reported in this filing17 Not reported in this filing1718 100,000
  1. Printed “-”, read as nil: subtotal_arithmetic: bs.current_assets.
  2. Printed “-”, read as nil: subtotal_arithmetic: bs.current_liabilities.
  3. Printed “-”; reading unresolved, so no amount is shown. Printed dash; no printed subtotal confirms a nil reading.
Notes and alternative reported figures (15)
  1. “Proposed dividend” is an issuer-specific line, not mapped to a shared definition: Note 12(ii): proposed dividend held in equity until declared.
  2. “Total equity and non current liabilities” is an issuer-specific line, not mapped to a shared definition: Net-assets layout: equals non-current assets plus net current assets.
  3. “Biological assets” is an issuer-specific line, not mapped to a shared definition: Note 6(i): orchards, plantations and livestock at fair value less costs to sell.
  4. “Non current receivables” is an issuer-specific line, not mapped to a shared definition: Note 23.
  5. “Biological assets – growing agricultural produce” is an issuer-specific line, not mapped to a shared definition: Note 6(ii): produce growing on the bearer plants.
  6. Printed under different labels across filings: “Biological assets - growing agricultural produce”; “Biological assets – growing agricultural produce”.
  7. Not reported in this filing: No current-tax-payable line for 2023 in the 2024 statement of financial position (p47).
  8. “Post employment benefit obligations” is an issuer-specific line, not mapped to a shared definition: Note 16: the current portion of the unfunded gratuity obligation.
  9. “Net current assets” is an issuer-specific line, not mapped to a shared definition: Current assets less current liabilities.
  10. “Total assets less current liabilities (unlabelled total)” is an issuer-specific line, not mapped to a shared definition: Unlabelled total closing the statement: non-current assets plus net current assets.
  11. “Less: fixed deposit – maturity over three months” is an issuer-specific line, not mapped to a shared definition: Note 25: deducted from cash and cash equivalents in the statement of financial position to give the cash-flow figure.
  12. Not reported in this filing: The 2024 report's cash note 25 (p93) defines cash and cash equivalents as cash at bank and short-term deposits, with no fixed-deposit deduction; the line first appears in the 2025 report (p102).
  13. “Financial assets held at amortised cost” is an issuer-specific line, not mapped to a shared definition: Note 21.
  14. Not reported in this filing: No current financial assets at amortised cost in the 2025 statement of financial position (p53).
  15. Annual report dated 2025-03-24 presents this line for this year: - (p47). Not shown in this column, which follows one filing's presentation.

Cash flow

Cash flow, KES thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), comparative reported in the annual report for 2024.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportcomparative in FY2024 filing
Cash generated from operations 817,439 450,555 855,095
Interest received 69,705 72,444 54,760
Income tax paid (33,993) (48,318) (260,563)
Net cash generated from operating activities 853,151 474,681 649,292
Purchase of property, plant and equipment (179,956) (204,065) (270,983)
Purchase and development of biological assets1 (28,781) (40,171) (25,747)
Proceeds from disposal of property, plant and equipment 491 5,480 2,568
Investment in fixed deposits over three months2 (60,000) –3 Not reported in this filing4
Proceeds from maturing financial assets held at amortised cost5 –3 100,000 Not reported in this filing6
Net cash used in investing activities (268,246) (138,756) (294,162)
Dividend paid (156,800) (470,400) (470,400)
Lease payments7 (61) (63) –8
Net cash used in financing activities (156,861) (470,463) (470,400)
Net increase/(decrease) in cash and cash equivalents9 428,044 (134,538) (115,270)
At start of year 1,106,684 1,408,131 1,408,744
Effect of exchange rate differences on cash and cash equivalents (1,525) (166,909) 114,657
At end of year 1,533,203 1,106,684 1,408,131
  1. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
  2. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_financing.
Notes and alternative reported figures (7)
  1. “Purchase and development of biological assets” is an issuer-specific line, not mapped to a shared definition: Investing activities (note 6(i)).
  2. “Investment in fixed deposits over three months” is an issuer-specific line, not mapped to a shared definition: Investing activities (note 25).
  3. Not reported in this filing: No fixed-deposit investment line in the 2024 statement of cash flows (p51).
  4. “Proceeds from maturing financial assets held at amortised cost” is an issuer-specific line, not mapped to a shared definition: Investing activities (note 21).
  5. Not reported in this filing: No 2023 amount is printed on this row of the statement of cash flows (p51).
  6. “Lease payments” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 17): principal and interest in one line.
  7. Printed under different labels across filings: “Net decrease in cash and cash equivalents”; “Net increase/(decrease) in cash and cash equivalents”.

Per share and shares

Per share and shares. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), comparative reported in the annual report for 2024.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportcomparative in FY2024 filing
Earnings / (loss) per share (per share)21 19.77 (6.72) 23.14
Shares in issue at year end (shares)3 19,600 thousand 19,600 thousand 19,600 thousand
Notes and alternative reported figures (3)
  1. Printed under different labels across filings: “Basic and diluted (loss)/earnings per ordinary share”; “Basic and diluted earnings/(loss) per ordinary share”.
  2. Earnings / (loss) per share: printed as “Basic and diluted earnings/(loss) per ordinary share”.
  3. Shares in issue at year end: printed as “Number of ordinary shares in issue (thousands)”.

Segments

Segment data not yet collected for this company in the pilot.

Dividends

Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.

Dividend events, the issuer's wording, and amounts as printed
Year endedEventWording as printedAmountUnitSource
31 Dec 2025 Dividend recommended, subject to shareholder approval the Directors will recommend the payment of a first and final dividend of 320% (2024: 160%) of par value equivalent to Shs 16.00 per ordinary share (Shs 313,600,000) no amount Annual report, p90
31 Dec 2025 Dividend proposed per share, as printed in a statement First and final dividend proposed for the year, per share 16.00 KES per share Annual report, p90
31 Dec 2025 Dividends paid (cash flow statement) Dividend paid (156,800) KES thousands Annual report, p57
31 Dec 2024 Dividend recommended, subject to shareholder approval dividend of 160% (2023: 480%) of par value equivalent to Shs 8.00 per ordinary share (Shs 156,800,000) no amount Annual report, p82
31 Dec 2024 Dividend proposed per share, as printed in a statement First and final dividend for the year, per share 8.00 KES per share Annual report, p90
31 Dec 2024 Dividend proposed per share, as printed in a statement First and final dividend proposed for the year, per share 8.00 KES per share Annual report, p82
31 Dec 2024 Dividends paid (cash flow statement) Dividend paid (470,400) KES thousands Annual report, p57
31 Dec 2023 Dividend proposed per share, as printed in a statement First and final dividend for the year, per share 24.00 KES per share Annual report, p82
31 Dec 2023 Dividends paid (cash flow statement) Dividend paid (470,400) KES thousands Annual report, p51

Sources

Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.

  • Kakuzi Plc Annual Report and Financial Statements for the Year ended 31 December 2025

    Year ended 31 December 2025 · Annual report · signed / final

    Audit: Deloitte & Touche LLP, unmodified opinion · signed

    Auditor's sign-off: Deloitte & Touche LLP; engagement partner CPA Fredrick Okwiri (practising certificate No. 1699)

    Final status: Auditors' report signed for Deloitte & Touche LLP (engagement partner CPA Fredrick Okwiri) and dated 24 March 2026 (PDF p49, page image); statements approved by the board on 24 March 2026 and signed by two directors (PDF p53, page image).

    Document date
    24 Mar 2026
    Published
    24 Mar 2026
    Auditor's report
    24 Mar 2026
    Board approval
    24 Mar 2026
    Retrieved by us
    7 Oct 2026 (not a publication date)
    Used for
    statement columns FY2025, FY2024
    Basis
    consolidated statements · KES thousands (printed “Shs'000”)
    • Key audit matters (PDF pp45-46), including the valuation of biological assets.
    • The statement of financial position uses the net-assets layout (equity and non-current liabilities against non-current assets plus net current assets); total assets and total liabilities are not printed and are recorded as not reported. Several subtotals, and the closing total, are printed without labels.
    • First and final dividend of Shs 16.00 per share recommended for 2025 (2024: Shs 8.00), 19,600 thousand shares (note 12).
    Technical details
    File
    112 pages, with a text layer
    SHA-256
    00b43d328d3c78aefedf75bd605e961c3a7a517b4993306134eec1c98e84dbc0
    Entity as printed
    Kakuzi Plc (the Company) and its subsidiaries (together, the Group)
    Issuer copy
    retrieved 2026-10-07T23:41:46Z

  • Kakuzi Plc Annual Report and Financial Statements for the year ended 31 December 2024

    Year ended 31 December 2024 · Annual report · signed / final

    Audit: Deloitte & Touche LLP, unmodified opinion · signed

    Auditor's sign-off: Deloitte & Touche LLP; engagement partner CPA Fredrick Okwiri (practising certificate No. 1699)

    Final status: Auditors' report signed for Deloitte & Touche LLP (engagement partner CPA Fredrick Okwiri) and dated 24 March 2025 (PDF p43, page image); statements approved by the board on 24 March 2025 and signed by two directors (PDF p47, page image).

    Document date
    24 Mar 2025
    Published
    27 Mar 2025
    Auditor's report
    24 Mar 2025
    Board approval
    24 Mar 2025
    Retrieved by us
    7 Oct 2026 (not a publication date)
    Used for
    statement columns FY2023
    Basis
    consolidated statements · KES thousands (printed “Shs'000”)
    • Key audit matters (PDF pp40-41), including the valuation of biological assets.
    • Net-assets layout; total assets and total liabilities are not printed. 'Proceeds from maturing financial assets held at amortised cost' (100,000) has no 2023 amount printed, and 'Lease payments' prints '-' for 2023.
    • First and final dividend of Shs 8.00 per share recommended for 2024 (2023: Shs 24.00) (note 12).
    • The text layer of the statement pages (PDF pp46-48, 51) encodes most figures and many labels in a private font mapping (for example '¾Ä¾ŕàÒÒ¾Ü' for 'non-current'); the page images are clear. These pages were read with OCR and compared with the renders.
    Technical details
    File
    104 pages, with a text layer
    SHA-256
    c8deb014bf2ae9090fe86dba6859896aacbb62d8ee6eca3971951b090e7bb337
    Entity as printed
    Kakuzi Plc (the Company) and its subsidiaries (together, the Group)
    Issuer copy
    retrieved 2026-10-07T23:41:49Z

Data notes

No figure-level notes beyond those in the tables.

Review status: every figure has been checked against its cited source page in an AI-assisted source verification (7 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.

Download

Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.

Kenya country page · Company methodology and coverage